首页 Opko健康(usOPK)-基本信息

Opko健康(usOPK)-基本信息

日报更新时间:

周报更新时间:04-11 03:39

行情信息

今开价:

最高价:

成交量:

昨收价:

最低价:

最新价:

行情图标
概要信息

中文名称:Opko健康


英文名称:OPKO Health


简介:OPKO Health, Inc.最初于1991年10月以cytoclonal制药股份有限公司的名字在特拉华注册成立,后来改为exegenics股份有限公司,其是一家跨国制药和诊断公司,旨在通过发现,开发和商业化专业知识和新的专有技术以建立行业领先的快速增长的大型医疗市场


电话:1-305-5754100


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Opko Health公司主要在美国及国际商从事新型与专利技术之发现、开发及商业化,公司分为2个部门来运作:生物制药(Biopharmaceutical)、诊断( Diagnostics)。Opko Health公司开发各种解决方案,用以诊断、治疗及预防各种疾病,包括:定点照护检验(POC)、分子诊断测试、实验室开发测试及专利药品与疫苗等,产品包括有: 4Kscore测试,为测量四种不同的前列腺衍生之血管增渗素蛋白质之血浆浓度。 Rayaldee,用于治疗第三期或第四期慢性肾脏病及维生素D不足患者之次发性副甲状腺机能亢进症。 Alpharen,为治疗长期血液透析的第五期患者之高血磷症。 CTP,hGH-CTP为治疗生长激素不足。 Factor VII-CTP,为治疗血友病A或B患者出血情况用之Factor VIII或Factor IX抑制剂。 Inspiromatic,一个粉末吸入器,用于治疗气喘、慢性阻塞性肺疾病、囊肿纤维化及其他呼吸疾病。 rolapitant,预防化疗引起的恶心和呕吐,以及专注于开发一个长时间作用之oxyntomdulinGLP-1/升糖素双倍受体促效剂。 Claros1免疫测定​​工具系统,提供快速血液检验结果,在定点照护检验装置下执行复杂的分析;药物为用于治疗癌症、心脏病、代谢失调及各种基因异常,以及临床开发治疗呼吸疾病的各种治疗药剂。 经营一个全方位服务之医学实验室,专攻泌尿科病理学。此外,Opko Health与Bristol-Myers Squibb Co.合作,研发诊断技术。

交易日期 交易人 职位 类型 交易份额 价格
2015-03-12 LOGAL ADAM E Chief Financial Officer Sell 38888 14.64
2015-03-12 LOGAL ADAM E Chief Financial Officer Sell 500 14.62
2015-03-12 LOGAL ADAM E Chief Financial Officer Sell 576 14.61
2015-03-12 LOGAL ADAM E Chief Financial Officer Sell 1500 14.65
2015-03-12 LOGAL ADAM E Chief Financial Officer Sell 24 14.56
2015-03-11 LOGAL ADAM E Chief Financial Officer Sell 4767 14.60
2015-03-11 LOGAL ADAM E Chief Financial Officer Buy 60000 1.16
2015-03-11 LOGAL ADAM E Chief Financial Officer Sell 3956 14.60
2015-03-11 LOGAL ADAM E Chief Financial Officer Buy 35000 1.65
2015-03-09 PHILLIP FROST ET AL Chief Executive Officer Buy 1000 13.79
2015-03-09 PHILLIP FROST ET AL Chief Executive Officer Buy 1755 13.79
2015-03-09 PHILLIP FROST ET AL Chief Executive Officer Buy 1800 14.00
2015-03-09 PHILLIP FROST ET AL Chief Executive Officer Buy 100 13.78
2015-03-09 PHILLIP FROST ET AL Chief Executive Officer Buy 745 13.77
2015-03-08 PHILLIP FROST ET AL Chief Executive Officer Buy 1800 13.94
2015-03-08 PHILLIP FROST ET AL Chief Executive Officer Buy 2400 13.97
2015-03-08 PHILLIP FROST ET AL Chief Executive Officer Buy 100 14.01
2015-03-08 PHILLIP FROST ET AL Chief Executive Officer Buy 100 14.02
2015-03-08 PHILLIP FROST ET AL Chief Executive Officer Buy 100 13.93
2015-03-08 PHILLIP FROST ET AL Chief Executive Officer Buy 1600 14.01
2015-03-08 PHILLIP FROST ET AL Chief Executive Officer Buy 1200 13.97
2015-03-08 PHILLIP FROST ET AL Chief Executive Officer Buy 100 14.07
2015-03-08 PHILLIP FROST ET AL Chief Executive Officer Buy 1700 14.07
2015-03-08 PHILLIP FROST ET AL Chief Executive Officer Buy 1700 13.93
2015-03-05 PHILLIP FROST ET AL Chief Executive Officer Buy 1617 14.24
2015-03-05 PHILLIP FROST ET AL Chief Executive Officer Buy 1000 14.13
2015-03-05 PHILLIP FROST ET AL Chief Executive Officer Buy 700 14.19
2015-03-05 PHILLIP FROST ET AL Chief Executive Officer Buy 1800 14.10
2015-03-05 PHILLIP FROST ET AL Chief Executive Officer Buy 1800 14.14
2015-03-05 PHILLIP FROST ET AL Chief Executive Officer Buy 400 14.20
第 页, 共 83 页 首页 上页 下页 末页

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Group One Trading, LP 2152442 0.35% 1225860 132.30% 2019-03-31
Fidelity Management & Research Company 4552713 0.74% -480683 -9.55% 2019-07-31
Northern Trust Investments Inc 6420278 1.04% 243420 3.94% 2019-07-31
Vanguard Investments Australia Ltd 7983568 1.30% 2618575 48.81% 2019-07-31
SSGA Funds Management Inc 10757980 1.75% 166615 1.57% 2019-07-31
State Street Corporation 20127594 3.27% 4485484 28.68% 2019-03-31
BlackRock Fund Advisors 20539493 3.34% 50041 0.24% 2019-07-31
Vanguard Group Inc 29655306 4.82% 1273653 4.49% 2019-03-31
BlackRock Inc 30190146 4.90% -86516 -0.29% 2019-03-31
Geode Capital Management, LLC 4527632 0.74% -3629162 -44.49% 2019-03-31
Dimensional Fund Advisors, Inc. 4329742 0.70% 166578 4.00% 2019-03-31
Northern Trust Investments N A 4020511 0.65% -119508 -2.89% 2019-03-31
Northern Trust Corp 4020511 0.65% -119508 -2.89% 2019-03-31
Oracle Investment Management Inc 3686194 0.60% -- -- 2019-03-31
Morgan Stanley - Brokerage Accounts 3372339 0.55% 1992341 144.37% 2019-03-31
State Street Global Advisors 3317083 0.54% 172500 5.49% 2019-07-31
Dimensional Fund Advisors LP 3110302 0.51% -23682 -0.76% 2019-07-31
Marshall Wace Asset Management Ltd 2904352 0.47% 2864471 7182.55% 2019-03-31
Canada Pension Plan Investment Board 2330376 0.38% 66976 2.96% 2019-03-31
Charles Schwab Investment Management Inc 2259566 0.37% 159070 7.57% 2019-03-31
Amvescap Plc. 2543839 0.41% 609222 31.49% 2018-12-31
First Manhattan Company 2786363 0.45% -1504350 -35.06% 2018-12-31
Invesco Capital Management LLC 3146390 0.51% 10672 0.34% 2019-05-31
BlackRock Asset Management Canada Ltd 7571682 1.23% 2145 0.03% 2019-05-31
Citigroup Inc 2129075 0.35% 1245743 141.03% 2018-12-31
IFP Advisors, Inc 2019318 0.33% -159792 -7.33% 2018-09-30
Goldman Sachs Group Inc 1710629 0.29% 152251 9.77% 2018-09-30
Frost Group LLC 20091062 3.43% 20091062 -- 2017-09-14
Phillip Frost 170550224 29.09% 170550224 -- 2017-09-14
BlackRock Institutional Trust Company NA 9943596 1.70% 331892 3.45% 2018-06-30
Millennium Management LLC 2178877 0.39% 1565216 255.06% 2018-03-31
Northern Trust Asset Management 803552 0.14% 9879 1.24% 2018-07-31
State Street Corp 15061058 2.69% -2874493 -16.03% 2018-06-30
Invesco PowerShares Capital Mgmt LLC 2142365 0.38% -303721 -12.42% 2018-06-30
Amitim Senior Pension Funds 1760048 0.31% -600000 -25.42% 2018-06-30
Morgan Stanley Smith Barney LLC 1620346 0.29% 212777 15.12% 2018-06-30
Merrill Lynch & Co Inc 1502907 0.27% 1295694 625.30% 2018-06-30
BMO Asset Management Inc 1405077 0.25% -- -- 2018-06-30
Weiss Multi-Strategy Advisers Llc 1250000 0.22% -41583 -3.22% 2018-06-30
RK Asset Management, LLC 1026018 0.18% 177961 20.98% 2018-06-30
BNY Mellon Investment Management 908395 0.16% 241064 36.12% 2018-06-30
UBS Securities LLC 1941938 0.35% 224392 13.06% 2018-03-31
MacKay Shields LLC 2799098 0.50% 2799098 -- 2018-03-31
Goldman, Sachs & Co. 938253 0.17% -37257 -3.82% 2018-03-31
TIAA-CREF Investment Management LLC 972174 0.17% -39707 -3.92% 2018-03-31
NORGES BANK 3870493 0.69% 1369669 54.77% 2017-12-31
Cornerstone Capital Management Holdings Llc 2051732 0.37% 606422 41.96% 2017-12-31
JAFFETILCHIN INVESTMENT PARTNERS, LLC 943039 0.17% -128018 -11.95% 2017-12-31
California Public Employees Retrmnt Sys 789156 0.14% 9800 1.26% 2017-09-30
Fidelity Management and Research Company 1533197 0.27% -3894983 -71.75% 2017-09-30
Deutsche Bank AG 1286055 0.23% 173465 15.59% 2017-09-30
Renaissance Technologies Corp 1077491 0.19% -538200 -33.31% 2017-09-30
Susquehanna Financial Group, LLLP 1926520 0.34% 1568193 437.64% 2017-06-30
Menora Mivtachim Life Insurance 3339693 0.60% 300000 9.87% 2016-09-30
Morgan Stanley & Co Inc 3251445 0.58% 26131 0.81% 2016-09-30
Clal Insurance Enterprises Holdings Ltd 2254025 0.40% -- -- 2016-09-30
Migdal Mutual Funds Ltd 1557122 0.28% -75010 -4.60% 2016-11-30
Bridger Management LLC 1523125 0.27% 450392 41.99% 2016-09-30
Jane H. Hsiao 29857879 4.00% 427863406 0.10% 1999-11-30
Frost Gamma Investments Trust 174719059 4.00% 2147483647 0.40% 1999-11-30
Phillip Frost, M.D. 177788010 4.00% 2147483647 0.40% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
MEDICAL BioHealth 858142 0.14% -- -- 2019-04-30
iShares Russell 2000 Value ETF 3118249 0.51% 48058 1.57% 2019-07-31
Vanguard Small Cap Growth Index Fund 5139456 0.83% 379812 7.98% 2019-06-30
Vanguard Extended Market Index Fund 5546421 0.90% -37733 -0.68% 2019-06-30
iShares Nasdaq Biotechnology ETF 6076949 0.99% 61877 1.03% 2019-07-30
iShares Russell 2000 ETF 7410980 1.20% 14509 0.20% 2019-07-30
Vanguard Total Stock Market Index Fund 7914113 1.29% 2618978 49.46% 2019-06-30
Vanguard Small Cap Index 9023740 1.47% 567406 6.71% 2019-06-30
SPDR 10443885 1.70% 162015 1.58% 2019-07-31
DFA US Small Cap Portfolio 1722852 0.28% -- -- 2019-05-31
State Street Russell Small Cap 1512887 0.25% 169200 12.59% 2019-07-31
NT R2000 Value Index Fund - Lending 916935 0.15% 81934 9.81% 2019-06-30
Northern Trust Russell 2000 Index DC NL 946565 0.15% 19108 2.06% 2019-06-30
Schwab US Small-Cap ETF 1167900 0.19% 1000 0.09% 2019-07-31
NT R2000 Index Fund - NL 1246848 0.20% 41876 3.48% 2019-06-30
NT R2000 Value Index Fund - Non-Lending 1289535 0.21% -- -- 2019-06-30
Fidelity 1302293 0.21% 157168 13.72% 2019-04-30
Direxion Daily S&P Biotech Bull 3X Shrs 1317069 0.21% 357358 37.24% 2019-04-30
State Street Russell Small/Mid Cap 1385444 0.23% -- -- 2019-07-31
Vanguard Health Care Index Fund 841270 0.14% -28464 -3.27% 2019-05-31
Invesco Dynamic Biotech & Genome ETF 2438099 0.40% -- -- 2019-05-30
iShares US Small Cap ETF (CAD-Hedged) 6506883 1.06% -10926 -0.17% 2019-05-30
Vanguard Small Cap Index Fund 8362420 1.36% 358707 4.48% 2019-03-31
BlackRock Extended Equity Market 700998 0.11% 85806 13.95% 2019-03-31
APO Medical Opportunities 692712 0.11% -- -- 2019-02-28
iShares Russell Mid-Cap ETF 833425 0.14% -487 -0.06% 2018-06-21
iShares Russell Mid-Cap Value ETF 880230 0.14% -- -- 2018-06-21
iShares Russell 1000 Value ETF 916045 0.15% 288 0.03% 2018-06-21
Schwab Small Cap Index Fund 633014 0.10% 10014 1.61% 2019-01-31
FCP MEDICAL BioHealth-Trends 768142 0.13% 215000 38.87% 2018-10-31
Fidelity Advisor 682700 0.12% -- -- 2018-11-30
BlackRock Russell 1000 Index Fund 971957 0.17% 2295 0.24% 2018-05-31
BlackRock Advantage Global Fund 808746 0.14% -- -- 2017-09-30
Vanguard Extended Market Idx Inv 4814476 0.86% -- -- 2018-07-31
AXA 2000 Managed Volatility K 487847 0.09% -- -- 2018-07-31
Vanguard Instl Ttl Stk Mkt Idx InstlPls 510547 0.09% -- -- 2018-07-31
BlackRock Extended Equity Market K 612929 0.11% 126833 26.09% 2018-06-30
Schwab Small Cap Index 599700 0.11% -- -- 2018-07-31
Fidelity Spartan 712532 0.13% -- -- 2018-07-31
Vanguard Total Stock Mkt Idx 8497541 1.52% 7958 0.09% 2018-07-31
iShares Nasdaq Biotechnology 6382613 0.88% -- -- 2018-09-12
Vanguard Small Cap Growth Index Inv 4828642 0.86% 78575 1.65% 2018-07-31
iShares Russell 2000 Value 3006707 0.42% -- -- 2018-09-12
DFA US Small Cap I 1722852 0.31% 553867 47.38% 2018-07-31
State Street Russell Small/Mid Cap Idx Fd Cl I 1088291 0.19% -- -- 2017-06-30
PowerShares Dynamic Biotech & Genome ETF 1347076 0.19% -- -- 2018-09-13
Northern Trust Russell 2000 Index Fund - DC - Non-Lending 803552 0.14% 9879 1.24% 2018-07-31
CREF Stock R1 756495 0.14% 186584 32.74% 2018-07-31
Vanguard Health Care ETF 738662 0.13% 6282 0.86% 2018-07-31
Schwab US Mid-Cap ETF 593829 0.10% 948 0.16% 2018-09-06
MainStay VP Mid Cap Core Svc 810774 0.14% -413272 -33.76% 2018-05-31
PowerShares FTSE RAFI US 1500 Sm-Mid ETF 408642 0.08% -- -- 2018-08-05
BlackRock Russell 2000 471063 0.08% 471063 -- 2018-06-30
BlackRock Russell 2500 459798 0.08% 902 0.20% 2018-06-30
iShares Russell 1000 Value 916045 0.19% 288 0.03% 2018-06-21
iShares Russell Mid-Cap Value 880230 0.18% -- -- 2018-06-21
iShares Russell Mid-Cap 833425 0.17% -487 -0.06% 2018-06-21
Gabelli Small Cap Growth AAA 319500 0.06% -- -- 2017-12-31
MainStay Cornerstone Growth A 466132 0.08% 292616 168.64% 2018-02-28
Rydex Biotechnology H 511700 0.09% 511700 -- 2017-12-31
iShares Russell 1000 Growth 867481 0.15% -- -- 2017-02-07
BlackRock Global SmallCap Inv A 725877 0.13% -- -- 2016-12-31
iShares Russell Mid-Cap Growth 719988 0.12% -- -- 2017-02-07
T. Rowe Price QM US Small-Cap Growth Eq 487700 0.09% -- -- 2016-12-31
SPDR® S&P Biotech ETF 2354591 0.50% 15332 0.70% 2015-11-19
Fidelity Spartan® Extended Mkt Indx Fd 1169405 0.20% -- -- 2015-09-30
PowerShares Dynamic Biotech&Genome Port 1102276 0.20% -- -- 2015-11-19
Rydex Biotechnology Fund 910540 0.20% -62400 -6.40% 2015-10-31
Hussman Strategic Growth Fund 750000 0.10% 191750 34.40% 2015-09-30
Catalyst Insider Buying Fund 715000 0.20% -150000 -17.30% 2015-06-30
CREF Stock Account 691969 0.10% 76510 12.40% 2015-09-30
Migdal Tel Aviv 100 Tracker 668486 0.20% 8978 1.40% 2015-08-31
Migdal Tel Aviv 25 Tracker 657837 0.10% -2134 -0.30% 2015-08-31
Fidelity® Select Biotechnology Portfolio 2721309 0.50% -- -- 2015-09-30

Phillip Frost Dr. Phillip Frost, MD, is Chairman & Chief Executive Officer at OPKO Health, Inc., Chairman at Teva Pharmaceutical Industries Ltd., Chairman of the Investment Committee at Peregrine Ventures, Chairman at Ladenburg Thalmann & Co., Inc., Chairman at Ladenburg Thalmann Financial Services, Inc., Chairman at Temple Emanu-El, a Member at The Florida Council of 100, a Member at Frost Group LLC, and Chairman at Lachema as. He is on the Board of Directors at Castle Brands, Inc., Mount Sinai Medical Center, University of Miami (Florida), Miami Jewish Home & Hospital for The Aged, Tel-Aviv University, Cocrystal Discovery, Inc., Fabrus, Inc., Morgan Solar, Inc., TransEnterix, Inc., Frost Gamma Investments Trust, and Smithsonian Institution. Dr. Frost was previously employed as Chairman by Ideation Acquisition Corp., Chairman by PROLOR Biotech, Inc., Chairman & Chief Executive Officer by eXegenics, Inc., Chairman by IVAX Diagnostics, Inc., Co-Vice Chairman & Governor by American Stock Exchange LLC, Chairman & Chief Executive Officer by IVAX Corp., Chairman by Key Pharmaceuticals, Inc., Chairman-Dermatology Department by Mount Sinai Medical Center of Florida, Inc., Chairman by Whitman Education Group, Inc., Chairman & Chief Executive Officer by IVAX Pharmaceuticals, Inc., Chairman & Chief Executive Officer by Sorrento Therapeutics, Inc., General Partner & Investment Committee Member by Incentive Technological Incubator Ltd., a Trustee by The Scripps Research Institute, and Vice Chairman by North American Vaccine, Inc. He also served on the board at BioZone Pharmaceuticals, Inc., SafeStitch Medical, Inc., Orthodontix, Inc., Cellular Technical Services Co., Inc., Continucare Corp., Northrop Grumman Corp., Protalix Biotherapeutics, Inc., Smithsonian Institution, and TransEnterix, Inc. He received his undergraduate degree from the University of Pennsylvania and a doctorate degree from the Albert Einstein College of Medicine.
Richard C. Pfenniger Richard C. Pfenniger is on the board of GP Strategies Corp. and 4 other companies. In the past he held the position of Chief Executive Officer of Vein Clinics of America, Inc., Chairman, President & Chief Executive Officer of Continucare Corp., Vice Chairman & Chief Executive Officer of Whitman Education Group, Inc. and Director at IVAX LLC. Richard C. Pfenniger received an undergraduate degree from Florida Atlantic University and a graduate degree from the University of Florida.
Richard C. Pfenniger Richard C. Pfenniger is on the board of GP Strategies Corp. and 4 other companies. In the past he held the position of Chief Executive Officer of Vein Clinics of America, Inc., Chairman, President & Chief Executive Officer of Continucare Corp., Vice Chairman & Chief Executive Officer of Whitman Education Group, Inc. and Director at IVAX LLC. Richard C. Pfenniger received an undergraduate degree from Florida Atlantic University and a graduate degree from the University of Florida.
Steven D. Rubin Mr. Steven D. Rubin is an Independent Director at Red Violet, Inc., an Independent Non-Executive Director at Chromadex Corp., an Independent Director at Eloxx Pharmaceuticals, Inc., an Independent Director at Cocrystal Pharma, Inc., an Independent Director at Castle Brands, Inc., an Independent Director at Non-Invasive Monitoring Systems, Inc., a Chairman at Neovasc, Inc., a Chairman at B-Balloon Ltd., a Director & Executive Vice President-Administration at OPKO Health, Inc. and a Secretary & Vice President at The Frost Group LLC. He is on the Board of Directors at Red Violet, Inc., Chromadex Corp., BioReference Laboratories, Inc., Eloxx Pharmaceuticals, Inc., Cocrystal Pharma, Inc., Castle Brands, Inc., Non-Invasive Monitoring Systems, Inc., Kidville, Inc. and OPKO Health, Inc. Mr. Rubin was previously employed as an Independent Director by Sevion Therapeutics, Inc., a Chairman by SciVac Therapeutics, Inc., an Independent Director by VBI Vaccines, Inc., an Independent Director by Cogint, Inc., a Director, Chief Executive & Financial Officer by Tiger X Medical, Inc., an Independent Director by OPKO Biologics Ltd., a Secretary & Director by Ideation Acquisition Corp., an Executive Vice President-Administration by eXegenics, Inc., an Independent Director by Dreams, Inc., a Secretary, Senior Vice President & General Counsel by IVAX Corp., a Secretary, Senior Vice President & General Counsel by Telergy, Inc., and a Secretary & General Counsel by General Binding Corp. He also served on the board at Eloxx Pharmaceuticals Ltd., BioZone Pharmaceuticals, Inc., clickNsettle.com, Inc., Cocrystal Discovery, Inc., Longfoot Communications Corp., Cellular Technical Services Co., Inc., SafeStitch Medical, Inc., Stearns Weaver Miller Weissler Alhadeff & Sitterson PA, BioCardia, Inc., IDI, Inc. (United States) and TransEnterix, Inc. He received his undergraduate degree from Tulane University (Louisiana) and a graduate degree from the University of Florida.
Richard Alan Lerner Founder of CovX Research LLC and Zebra Biologics, Inc., Richard Alan Lerner is Professor at The Scripps Research Institute, Member of National Academy of Sciences and Member of Royal Swedish Academy of Sciences and on the board of 7 other companies. In his past career Dr. Lerner occupied the position of Scientific Advisor at 5AM Venture Management LLC and Chairman of Scientific Advisory Board at Bay City Capital LLC. He received an undergraduate degree from Northwestern University and a doctorate from Stanford University School of Medicine.
Charles W. Bishop Charles W. Bishop founded Proventiv Therapeutics LLC. Dr. Bishop is Chief Executive Officer-OPKO Renal at OPKO Health, Inc. He previously was Principal at Procter & Gamble Co., President, Chief Executive Officer & Director at Cytochroma, Inc., President of Proventiv Therapeutics LLC and Chief Scientific Officer of Bone Care International, Inc. Dr. Bishop received an undergraduate degree from the University of Virginia and a doctorate from Virginia Polytechnic Institute & State University.
Lin-Tsing Yu Lin-Tsing Yu is on the board of OPKO Health, Inc. and Professor at National Taiwan University, Director & Professor at The Institute of Stem Cell & Translational Cancer Research and Professor at the University of California San Diego. Dr. Yu previously held the position of Professor at Chang Gung University and Associate Director at Academia Sinica. She received a doctorate from National Taiwan University, a graduate degree from Yale University and a doctorate from The University of Chicago.
Stephen A. Strugnell Stephen A. Strugnell is Senior Director-Scientific Affairs at OPKO Health, Inc. He received a doctorate from Queen's University.
Jane H. Hsiao Jane H. Hsiao is a businessperson who founded IVAX LLC and Great Eastern Bank of Florida and who has been at the head of 7 different companies. Dr. Hsiao holds the position of Chairman & Chief Executive Officer at Non-Invasive Monitoring Systems, Inc. and Vice Chairman & Chief Technical Officer at OPKO Health, Inc. Jane H. Hsiao is also Vice President for The Frost Group LLC and on the board of 5 other companies. In the past Dr. Hsiao held the position of President at Innotech Laboratories, Inc., Vice President at Baker Norton Pharmaceuticals, Chairman, President & Chief Executive Officer for IVAX Animal Health, Inc., Chairman of Cellular Technical Services Co., Inc., Chairman, President & Chief Executive Officer at DVM Pharmaceuticals, Inc., Chairman for SafeStitch Medical, Inc., President & Director at Aero Pharmaceuticals, Inc., Vice Chairman & Chief Technical Officer at eXegenics, Inc., Vice Chairman-Technical Affairs at IVAX LLC, General Partner for HSU Gamma Investments LP and Director at Great Eastern Bank of Florida. Dr. Hsiao received a doctorate from the University of Illinois, an undergraduate degree from National Taiwan University and an MBA from Nova Southeastern University, Inc.
John A. Paganelli John A. Paganelli occupies the position of Chairman of Pharos Systems International. He is also on the board of Western New York Energy LLC, OPKO Health, Inc. and Paul Smith's College of Arts & Sciences and Managing Partner at Pharos Systems Partners LLC and Partner at RFG Associates. Mr. Paganelli previously occupied the position of President & Chief Executive Officer at Transamerica Life Insurance Co., Executive Vice President of PEG Capital Management, Inc. and Chairman of eXegenics, Inc.
Richard M. Krasno Richard M. Krasno is on the board of Ladenburg Thalmann Financial Services, Inc. and 4 other companies. In the past Dr. Krasno held the position of Deputy Assistant Secretary at Education Assistance Foundation, Chairman of UNC Health Care System, President & Chief Executive Officer for Institute of International Education, Inc. and President at Monterey Institute of International Studies. He received a doctorate from Stanford University and an undergraduate degree from the University of Illinois.
Kate Inman Ms. Kate Inman is a Secretary & General Counsel at OPKO Health, Inc.
Adam E. Logal Adam E. Logal holds the position of Chief Financial & Accounting Officer, Senior VP at OPKO Health, Inc. and Chairman of Xenetic Biosciences, Inc. He is also on the board of BioReference Laboratories, Inc. In his past career Mr. Logal held the position of Chief Financial & Accounting Officer for Nabi Biopharmaceuticals and Finance Director, Secretary, Treasurer & CAO at eXegenics, Inc.
Stephen A. Strugnell Stephen A. Strugnell is Senior Director-Scientific Affairs at OPKO Health, Inc. He received a doctorate from Queen's University.
Stephen A. Strugnell Stephen A. Strugnell is Senior Director-Scientific Affairs at OPKO Health, Inc. He received a doctorate from Queen's University.
Stephen A. Strugnell Stephen A. Strugnell is Senior Director-Scientific Affairs at OPKO Health, Inc. He received a doctorate from Queen's University.
Thomas Nusbickel Thomas Nusbickel is Chief Commercial Officer of OPKO Health, Inc.
Anne Marie Fields Anne Marie Fields occupies the position of VP-Corporate Communications & Investor Relations at Intec Pharma Ltd.
Robert S. Fishel Founder of NewPace Ltd. and Florida Electrophysiology Associates, Robert S. Fishel presently occupies the position of President, Chief Executive Officer & Director at Florida Electrophysiology Associates, President & Director at ALSAR LP, Director & Chief Medical Officer at NewPace Ltd., Director & Senior managing Partner at Renaissance Properties, Inc. and Director & Partner at Catalyst Development Partners LLC. Robert S. Fishel is also on the board of OPKO Health, Inc. and Associate Professor at Charles E. Schmidt College of Medicine and Director-Cardiac Electrophysiology at The Community Hospital Group, Inc. Dr. Fishel previously held the position of Director-National Electrophysiology Research at Hospital Corp. of America.

量化对比

全部评论 1

  • Opko健康短线飙升,目前上涨超10%。

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐